CRISPR-Cas13

CRISPR-Cas13

A nucleic acid editing technology that targets RNA, analogous to the CRISPR-Cas9 system

CRISPR-Cas13 is an RNA targeting and editing system based on the bacterial immune system that protects them from viruses. Cas13, previously known as C2c2, is the effector protein that targets and cleaves invading nucleic acids from viruses in type VI CRISPR-Cas systems. The CRISPR-Cas13 system is analogous to the CRISPR-Cas9 system. However, unlike Cas-9 which targets DNA, Cas-13 targets and cleaves single stranded RNA. Cas-13 was first discovered in L. shahii, a species of the Leptotrichia bacteria while researchers were looking for previously unidentified CRISPR systems. Members of Cas13, Cas13a and Cas13b are being developed for therapeutic gene correction at the RNA level and detection of viral pathogens.

Timeline

October 25, 2017
June 2, 2016

Paper published on in vivo RNA targeting

People

Name
Role
LinkedIn

Eugene Koonin

Primary Investigator

Feng Zhang

Primary Investigator

Pardis C. Sabeti

Primary Investigator

Further reading

Title
Author
Link
Type
Date

C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

Abudayyeh et al.

Academic paper

CRISPR/Cas13 as a Tool for RNA Interference

Zahir Ali

Academic paper

New Version of CRISPR, Developed by Feng Zhang–Led Team, Can Target and Edit RNA

Alex Philippidis

Academic paper

RNA editing with CRISPR-Cas13

David B. T. Cox

Academic paper

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Jim Daley
April 23, 2020
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.